press release RSS



SENTE® and Skinuva® Partnership to Promote innovative topical scar therapy

SENTÉ®, an innovative specialty aesthetics company, is pleased to announce a partnership with Skinuva® as the exclusive US Professional Sales Partner of Skinuva® Scar.   Skinuva® Scar is a patented, physician-designed scar cream clinically proven to be more effective than silicone cream in improving the appearance of scars supported by 5 publications in peer-reviewed medical literature.   There has been a lack of advancement in silicone creams since their introduction in the 1990s. Skinuva® Scar is changing the way scars are treated with selective synthetic Growth Factors and other clinically proven ingredients in its formulation.   “As a long-time SENTÉ® customer in my Beverly Hills Oculoplastic practice, we could not have found a better partner and ambassador for the Skinuva®...

Continue reading



SENTÉ Announces New Collaborations with Galderma Laboratories, L.P. and The HydraFacial™ Company

New collaborations will increase access to SENTÉ’s patented sulfated glycosaminoglycan analog technology for aesthetic providers and their patients seeking innovative skin rejuvenation products Carlsbad, Calif., December 11, 2018 – SENTÉ, an innovative specialty aesthetics company, broadens reach with strategic collaborations to further expand their disruptive professional grade skin care product portfolio. Both collaborations will offer consumers the opportunity to experience SENTÉ’s patented Sulfated Glycosaminoglycan (SuGAG) analog technology clinically proven to deliver rapid skin rejuvenation. “Most people associate hyaluronic acid with the term glycosaminoglycan (GAG) and although it’s commonly found in skin care because of its ability to attract water, there are other GAGs – specifically sulfated GAGs – that can offer more.  Sulfated GAGs regulate many cell functions, and heparan...

Continue reading



SENTÉ Announces Issuance of a New United States Patent For Heparan Sulfate

San Diego, Calif., Oct. 17, 2016 — SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide. “The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction” said Laurent Combredet, Chief...

Continue reading



SENTÉ Appoints Laurent Combredet As President & Chief Executive Officer

SAN DIEGO, February 9, 2016 (GLOBE NEWSWIRE) – SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the appointment of Laurent Combredet as President and Chief Executive Officer. “Laurent is a well respected and strategic leader in the aesthetics dermatology field and we are excited to leverage his leadership and experience to help take the company to the next level,” said Faheem Hasnain, Chairman of the Board of Directors of SENTÉ. “Laurent is a tremendous addition to SENTÉ and I look forward to his strategic insight as we further position the company to be a major contender in the aesthetics industry.” Mr. Combredet brings to...

Continue reading



SENTÉ Completes $5M Capital Raise

Capital To Further Expand Commercial Operations And Broaden Product Portfolio SAN DIEGO, February 5, 2016 (GLOBE NEWSWIRE) – SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth. “We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will...

Continue reading